© 2005 European Society of Cardiology
Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure
Department of Cardiology, Medical University of Vienna Waehringer Guertel 18-20, A-1090 Vienna, Austria
* Corresponding author. Tel.: +43 1 40400 4614; fax: +43 1 4081148. E-mail address: deddo_moertl{at}yahoo.de
 |
Abstract |
|---|
Background: Both levosimendan and prostaglandin E1 (PGE1) have beneficial effects on hemodynamic parameters and outcome compared to dobutamine in decompensated chronic heart failure (CHF).
Aims: We compared short-term effects of levosimendan versus PGE1 on hemodynamic parameters and B-type natriuretic peptide levels (BNP) in patients with decompensated CHF.
Methods and results: 73 patients (cardiac index <2.5 L/min/m2 pulmonary capillary wedge pressure (PCP)> 15 mmHg) with decompensated CHF were randomised to treatment with either a 24 h-infusion of levosimendan (n=38) or a chronic infusion of PGE1 (n=35). Hemodynamic parameters and BNP were measured at baseline, 24 and 48 h, BNP levels were also measured after 1 week. Baseline characteristics including concomitant medication were similar in both groups. Levosimendan and PGE1 increased cardiac output (CO) after 24 and 48 h. Levosimendan increased CO twice as much as PGE1 (24 h: Levosimendan +1.1±0.1 L/min, PGE1 +0.6±0.1 L/min, p>0.001). Both drugs produced a comparable reduction in PCP and pulmonary artery pressure after 24 and 48 h. Levosimendan decreased BNP by 28% after 24 h and 22% after 48 h, but effects disappeared after 1 week. In contrast, PGE1 decreased BNP by 15% after 48 h (no change at 24 h), but a decrease of 20% was sustained at 1 week.
Conclusions: The differential beneficial effects of levosimendan (greater increase in CO) and PGE1 (sustained decrease in BNP) may have a potential impact on clinical outcome.
Key Words: Levosimendan • Prostaglandin E1 • B-type natriuretic peptide • Decompensated heart failure • Hemodynamic • Cardiac output
Received March 29, 2004; Revised September 8, 2004; Accepted May 5, 2005
1 Consultant for Abbott Laboratories Austria.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Berger, D. Moertl, M. Huelsmann, A. Bojic, R. Ahmadi, I. Heissenberger, and R. Pacher Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure Eur J Heart Fail, February 1, 2007; 9(2): 202 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Parissis, D. Farmakis, and D. T. Kremastinos Levosimendan therapy in decompensated chronic heart failure: Favourable haemodynamic and neurohormonal effects but for how long? Eur J Heart Fail, March 1, 2006; 8(2): 215 - 215. [Full Text] [PDF]
|
|
|
|
|
|
C. S. McLachlan and P. Mossop Levosimendan and plasma BNP levels: Do inflammatory cytokines regulate BNP in chronic decompensated heart failure? Eur J Heart Fail, March 1, 2006; 8(2): 216 - 217. [Full Text] [PDF]
|
|
|
|
|
|
D. Moertl Response to Letters to the Editor: Short-term effects of levosimendan and prostaglandin E1 on haemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure Eur J Heart Fail, March 1, 2006; 8(2): 218 - 218. [Full Text] [PDF]
|
|